Given the ongoing Covid-19 outbreak , the NCPE Annual Symposium "Update on Pharmacoeconomics in the Irish Healthcare Setting" is being postponed until later this year.
The NCPE recommends that olaparib (Lynparza®) for this indication not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that burosumab (Crysvita®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments**